Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-... von Heigener, D.F, Deppermann, K.M, Pawel, J.v, Fischer, J.R, Kortsik, C, Bohnet, S, Eiff, M.v, Koester, W, Thomas, M, Schnabel, P.A, Reck, M

Volltext

Palliative Care Concepts in Respiratory Disease von Heigener, D.F., Rabe, K.F.

Volltext

Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial von Bozorgmehr, F., Hommertgen, A., Lasitschka, F., Krisam, J., Debus, J., Fischer, J.R., Bischof, M., Atmaca, A., Wetzel, S., Faehling, M., Bottke, D., Grohe, C., Engel-Riedel, W., Ingenhoff, E., Heigener, D.F., Reinmuth, N., Schumann, C., Wermke, M., Thomas, M., Rieken, S.

Volltext

Management of non-small-cell lung cancer: recent developments von Reck, Martin, PD Dr, Heigener, David F, MD, Mok, Tony, Prof, Soria, Jean-Charles, Prof, Rabe, Klaus F, Prof

Volltext

1502TiPFostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer: The FORCE trial von Bozorgmehr, F, Hommertgen, A, Lasitschka, F, Krisam, J, Debus, J, Fischer, J R, Bischof, M, Atmaca, A, Wetzel, S, Faehling, M, Bottke, D, Grohe, C, Engel-Riedel, W, Ingenhoff, E, Heigener, D F, Reinmuth, N, Schumann, C, Wermke, M, Thomas, M, Rieken, S

Volltext

A cost analysis of treatment with bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-... von Heigener, D. F., Wiesner, C., Aultman, R.

Volltext

The cost-effectiveness of bevacizumab plus cisplatin and gemcitabine (BCG) compared with pemetrexed plus cisplatin (PC) induction treatment of advanced non-squamous non-small cell... von Bischoff, H., Hermes, A., Gatzemeier, U., Heigener, D. F., Cesaro-Tadic, S., Walzer, S.

Volltext

Was sollte der Pneumologe über Palliativmedizin wissen? von Nehls, W., Heigener, D. F.

Volltext

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer von Vergnenègre, Alain, Ray, Joshua A, Chouaid, Christos, Grossi, Francesco, Bischoff, Helge G, Heigener, David F, Walzer, Stefan

Volltext

Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): Final results of a randomised phase III trial von Heigener, D. F., Freitag, L., Eschbach, C., Huber, R. M., Fink, T., Hummler, S., Banik, N., Wolf, M.

Volltext

Die medikamentöse Therapie des metastasierten nicht-kleinzelligen Lungenkarzinoms von Heigener, D. F., Reinmuth, N., Reck, M.

Volltext

PCN105 COST SAVINGS ASSOCIATED WITH BEVACIZUMAB-BASED THERAPY IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY von Schmidt, E, Bischoff, HG, Heigener, DF, Stanisic, S, Walzer, S

Volltext

PCN82 COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCE... von Bischoff, HG, Hermes, A, Heigener, DF, Cesaro-Tadic, S, Walzer, S, Nuijten, M

Volltext

Immuntherapie des Lungenkarzinoms von Heigener, D. F, Steffen, P, Reck, M

Volltext

Immuntherapie des Lungenkarzinoms: Zwischen Hoffnung und Hype von Heigener, D. F., Steffen, P., Reck, M.

Volltext

Lungentumor, Heiserkeit, Soor und akutes Abdomen bei einer Nieraucherin von Kanappilly, A., Heigener, D.F., Schröder, T.H., Stellmacher, F., Rabe, K.F., Welker, L.

Volltext

Neuroendocrine Tumors of the Bronchopulmonary System (Typical and Atypical Carcinoid Tumors): Current Strategies in Diagnosis and Treatment. Conclusions of an Expert Meeting Februa... von Hörsch, D, Schmid, K.W, Anlauf, M, Darwiche, K, Denecke, T, Baum, R. P, Spitzweg, C, Grohé, C, Presselt, N, Stremmel, C, Heigener, D. F, Serke, M, Kegel, T, Pavel, M, Waller, C. F, Deppermann, K.-M, Arnold, R, Huber, R. M, Weber, M. M, Hoffmann, H

Volltext bestellen

Targeting of MEK in lung cancer therapeutics von Heigener, David F, Dr, Gandara, David R, Prof, Reck, Martin, MD

Volltext

Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients von Kuempers, C., van der Linde, L. I. S., Reischl, M., Vogel, W., Stellmacher, F., Reck, M., Heigener, D., Rabe, K. F., Kirfel, J., Perner, S., Welker, L.

Volltext

Shift in bacterial etiology from the CAPNETZ cohort in patients with community-acquired pneumonia: data over more than a decade von Braeken, D. C. W., Essig, A., Panning, M., Hoerster, R., Nawrocki, M., Dalhoff, K., Suttorp, N., Welte, T., Pletz, M. W., Witzenrath, M., Rohde, G. G. U., Rupp, J.

Volltext